1Department of pharmacology, School of Pharmaceutical Sciences, Research Scholar, VELS Institute of Science Technology & Advanced Studies, VELS University, Pallavaram, Chennai, Tamil Nadu (state), India
2Department of pharmacology, prof & Head, School of Pharmaceutical Sciences, VELS Institute of Science Technology & Advanced Studies, VELS University, Pallavaram, Chennai, Tamil Nadu (state), India
*Corresponding author: Noulla Saraswathi, Department of Pharmacology, School of Pharmaceutical Sciences, Research Scholar, VELS Institute of Science Technology & Advanced Studies, VELS University, Pallavaram, Chennai, Tamil Nadu (state), India. Email: chakri0231@gmail.com
Background: Parkinson's disease is a progressive neurodegenerative condition marked by the loss of dopaminergic neurons along with the emergence of both motor and non-motor symptoms. Natural polyphenols, like resveratrol, have shown considerable neuroprotective effects due to their antioxidant and anti-inflammatory qualities. Nevertheless, the clinical use of resveratrol is hindered by its poor solubility, rapid metabolism, and low bioavailability. The purpose of this review is to highlight recent developments in brain-targeted nanocarrier systems aimed at enhancing the delivery and therapeutic effectiveness of resveratrol for treating Parkinson's disease.
Methods: A thorough search of the literature was performed using electronic databases, such as PubMed, Scopus, ScienceDirect, and Google Scholar, focusing on studies published between 2018 and 2026. Keywords associated with resveratrol, nanocarriers, targeting the brain, and Parkinson's disease were utilized. After applying specific inclusion and exclusion criteria, around 40 pertinent studies were selected for analysis.
Findings: Different nanocarrier systems, such as liposomes, polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, and nanoemulsions, have been explored to improve the delivery of resveratrol to the brain. These systems enhance drug stability, increase bioavailability, aid in crossing the blood-brain barrier, and support targeted delivery to neurons. Numerous experimental studies have shown that nano-formulated resveratrol exhibits greater neuroprotective effects compared to free resveratrol.
Conclusion: In conclusion, drug delivery systems based on nanocarriers are a promising way to get around the pharmacokinetic problems with resveratrol and make treatment for Parkinson's disease more effective. Subsequent research concentrating on clinical assessment and sophisticated targeting methodologies may augment the efficacy of nano-resveratrol formulations in the management of neurodegenerative diseases.
Keywords: Resveratrol, Nanocarriers, Brain targeting, Parkinson's disease, Neuroprotection, Nanomedicine
How to cite this article: Saraswathi N, Darwin CR. Brain-Targeted Nanocarriers of Resveratrol for the Treatment of Parkinson's Disease: A Comprehensive Review. Int J Drug Deliv Technol. 2026;16(12s): 945-958. DOI: 10.25258/ijddt.16.12s.109
Source of support: Nil.
Conflict of interest: None